XNASQNTM
Market cap123mUSD
Dec 24, Last price
3.17USD
1D
-1.25%
1Q
-16.58%
IPO
-25.76%
Name
FSD Pharma Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
46.31%
Rev. gr., 5y
69.97%
Revenues
0k
Net income
-19m
L-20.40%
CFO
-11m
L-61.09%
Earnings
Mar 26, 2025
Profile
FSD Pharma Inc., a biotechnology company, operates in the pharmaceutical research and development business. Its lead candidate is FSD201, a palmitoylethanolamide for the treatment of inflammatory diseases. The company is also involved in the research and development of Lucid-Psych, a molecular compound identified for the treatment of mental health disorders; and Lucid-MS, a molecular compound identified for the treatment of neurodegenerative disorders. FSD Pharma Inc. is headquartered in Toronto, Canada.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑08 | 2015‑08 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 31,885 | 27,250 | 33,708 | ||||||
Unusual Expense (Income) | |||||||||
NOPBT | (31,885) | (27,250) | (33,708) | ||||||
NOPBT Margin | |||||||||
Operating Taxes | (1) | (3,382) | 1,468 | ||||||
Tax Rate | |||||||||
NOPAT | (31,885) | (23,868) | (35,176) | ||||||
Net income | (18,565) -20.40% | (23,322) -34.13% | (35,406) 8.21% | ||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (2,958) | (1,926) | 38,341 | ||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 339 | 478 | 425 | ||||||
Long-term debt | 39 | 254 | 386 | ||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (4,026) | (17,099) | (35,267) | ||||||
| Cash flow | |||||||||
Cash from operating activities | (11,026) | (28,333) | (20,746) | ||||||
CAPEX | (32) | (364) | (500) | ||||||
Cash from investing activities | (275) | 12,123 | 269 | ||||||
Cash from financing activities | (3,184) | (2,069) | 38,212 | ||||||
FCF | (38,354) | (21,722) | (33,390) | ||||||
| Balance | |||||||||
Cash | 3,495 | 17,004 | 35,418 | ||||||
Long term investments | 909 | 828 | 660 | ||||||
Excess cash | 4,404 | 17,831 | 36,078 | ||||||
Stockholders' equity | (17,228) | (101) | 26,410 | ||||||
Invested Capital | 33,651 | 31,160 | 28,277 | ||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 39,589 | 38,732 | 34,945 | ||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | (29,333) | (22,715) | (29,663) | ||||||
EV/EBITDA | |||||||||
Interest | 49 | 69 | |||||||
Interest/NOPBT | |||||||||